Bicara Therapeutics Inc. (BCAX) Price & Analysis

Compare

57 Followers

BCAX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$7.80 - $28.09

Previous CloseN/A

Volume80.52K

Average Volume (3M)301.51K

Market Cap

$653.66M

Enterprise Value$72.30M

Total Cash (Recent Filing)$436.61M

Total Debt (Recent Filing)$2.24M

Price to Earnings (P/E)―

Beta1.71

Next Earnings

Nov 18, 2025

EPS Estimate

-0.54

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.50

Shares Outstanding54,562,840

10 Day Avg. Volume280,598

30 Day Avg. Volume301,510

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.11

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.06K

Enterprise Value/Ebitda-0.60

Forecast

1Y Price Target

$31.67

Price Target Upside172.55% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe combination of ficerafusp alfa 1500mg + Keytruda elicited a 54% confirmed overall response rate and a 21% complete response rate in the total evaluable study population, which appears meaningfully superior to results from similar patient populations.

Financial PerformanceBicara ended 2Q25 with cash, cash equivalents, and marketable securities of $436.6M, which should be sufficient to fund operations significantly beyond major upcoming data catalysts.

Survival RatesFrom a survival perspective, ficerafusp alfa 1500mg + Keytruda demonstrated a median progression-free survival of 9.9 months and a median overall survival of 21.3 months, which is notable compared to real-world data.

Bears Say

Clinical RisksRisks include negative clinical results with ficerafusp alfa, delays in advancing into registrational trials, and failure to achieve favorable clinical results in other indications.

Competitive PressurePressure is on Merus to outperform Bicara, with Bicara presenting a more competitive dataset.

Bicara Therapeutics Inc. News

Bicara Therapeutics initiated with a Buy at JonesResearch

JonesResearch initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $22 price target The firm says...

5d ago

BCAX

Bicara Therapeutics price target lowered to $40 from $41 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Bicara Therapeutics (BCAX) to $40 from $41...

23d ago

BCAX

Bicara Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler analyst Kelsey Goodwin initiated coverage of Bicara Therapeutics (BCAX) with an Overweight rating and $36 price...

26d ago

BCAX

Bicara Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler analyst Kelsey Goodwin initiated coverage of Bicara Therapeutics (BCAX) with an Overweight rating and $36 price...

26d ago

BCAX

Bicara Therapeutics Reports Q2 2025 Results and Progress

Bicara Therapeutics Inc. ( ($BCAX) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

BCAX

Promising Clinical Developments and Financial Stability Drive Buy Rating for Bicara Therapeutics

In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc.,...

1M ago

BCAX

Bicara Therapeutics reports Q2 EPS (50c), consensus (54c)

“We continue to make excellent progress with the development of ficerafusp alfa,” said Claire Mazumdar, PhD, MBA, Chief...

1M ago

BCAX

Bicara Therapeutics expects cash to fund operations into 1H of 2029

As of June 30, 2025, Bicara had cash and cash equivalents of $436.6 million, compared to $489.7 million...

1M ago

BCAX

Bicara Therapeutics Elects New Directors at Annual Meeting

The latest announcement is out from Bicara Therapeutics Inc. ( ($BCAX) ). On June 9, 2025, Bicara Therapeutics...

3M ago

BCAX

Bicara Therapeutics Expands Boston Headquarters with New Lease

An update from Bicara Therapeutics Inc. ( ($BCAX) ) is now available. On June 2, 2025, Bicara Therapeutics...

3M ago

BCAX

Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: Analyst Reiterates Buy Rating with Strong Clinical Results and $41 Price Target

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Bicara Therapeutics Inc. (BCAX – Research...

3M ago

BCAX

Promising Efficacy of Bicara Therapeutics’ Ficera in Combination with Pembro for HPV-Negative HNSCC Justifies Buy Rating

Analyst Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report)...

3M ago

BCAX

Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

It’s time for a roundup of all the biggest stock market stories traders need to catch up on from Friday morning! ...

4M ago

ADI

BAH

Wells upgrades Bicara to Equal Weight with thesis played out

Wells Fargo upgraded Bicara Therapeutics (BCAX) to Equal Weight from Underweight with an unchanged price target of $8....

4M ago

BCAX

BCAX FAQ

What was Bicara Therapeutics Inc.’s price range in the past 12 months?

Bicara Therapeutics Inc. lowest stock price was $7.80 and its highest was $28.09 in the past 12 months.

What is Bicara Therapeutics Inc.’s market cap?

Bicara Therapeutics Inc.’s market cap is $653.66M.

When is Bicara Therapeutics Inc.’s upcoming earnings report date?

Bicara Therapeutics Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 65 days.

How were Bicara Therapeutics Inc.’s earnings last quarter?

Bicara Therapeutics Inc. released its earnings results on Aug 12, 2025. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.554 by $0.054.

Is Bicara Therapeutics Inc. overvalued?

According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bicara Therapeutics Inc. pay dividends?

Bicara Therapeutics Inc. does not currently pay dividends.

What is Bicara Therapeutics Inc.’s EPS estimate?

Bicara Therapeutics Inc.’s EPS estimate is -0.54.

How many shares outstanding does Bicara Therapeutics Inc. have?

Bicara Therapeutics Inc. has 54,562,840 shares outstanding.

What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?

Bicara Therapeutics Inc. reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.554. Following the earnings report the stock price went up 4.805%.

Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?

Currently, no hedge funds are holding shares in BCAX

Bicara Therapeutics Inc. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-32.71%

Trailing 12-Months

Asset Growth

117.25%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bicara Therapeutics Inc.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Bicara Therapeutics Inc. (BCAX) Earnings & Revenues

Historic Earnings Reports

BCAX Stock 12 Month Forecast

Average Price Target

$31.67

▲(172.55% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","28":"$28","49":"$49","17.5":"$17.5","38.5":"$38.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,17.5,28,38.5,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.9,14.676923076923078,17.453846153846154,20.230769230769234,23.00769230769231,25.784615384615385,28.56153846153846,31.338461538461537,34.11538461538461,36.89230769230769,39.669230769230765,42.44615384615385,45.223076923076924,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.9,13.420769230769231,14.941538461538462,16.462307692307693,17.983076923076926,19.503846153846155,21.024615384615387,22.54538461538462,24.06615384615385,25.586923076923078,27.10769230769231,28.628461538461544,30.149230769230776,{"y":31.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.9,11.6,11.3,11,10.7,10.4,10.1,9.8,9.5,9.2,8.9,8.6,8.3,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.41,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.43,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.43,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.42,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.62,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.3,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.9,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >